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Abstract  
Familial aggregation, coupled with ethnic variation in incidence, suggests that 
inherited susceptibility plays a role in the development of lymphoma, and the search 
for genetic risk factors has highlighted the contribution of the Human Leukocyte 
Antigen (HLA) complex.  In a landmark study published almost fifty years ago, 
Hodgkin lymphoma was the first disease to be associated with HLA variation.  It is 
now clear that EBV-positive and -negative Hodgkin lymphoma are strongly 
associated with specific HLA polymorphisms but these differ by EBV status of the 
tumours.  HLA class I alleles are consistently associated with EBV-positive Hodgkin 
lymphoma while a polymorphism in HLA class II is the strongest predictor of risk of 
EBV-negative Hodgkin lymphoma.  Recent investigations, particularly genome wide 
association studies, have also revealed associations between HLA and common 
types of non-Hodgkin lymphoma.  Follicular lymphoma is strongly associated with 
two distinct haplotypes in HLA class II whereas diffuse large B-cell lymphoma is 
most strongly associated with HLA-B*08.  Although chronic lymphocytic leukaemia is 
associated with variation in HLA class II, the strongest signals in genome wide 
association studies are from non-HLA polymorphisms, suggesting that inherited 
susceptibility is explained by co-inheritance of multiple low risk variants.  
Associations between B-cell derived lymphoma and HLA variation suggest that 
antigen presentation, or lack of, plays an important role in disease pathogenesis but 
the precise mechanisms have yet to be elucidated. 
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Introduction  
Mature B-cell neoplasms account for 90% of all lymphomas globally and are divided 
into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) (1).  HL is one of 
the most common lymphomas in the developed world and comprises two entities, 
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin 
lymphoma (cHL), which account for <5% and >95% of cases, respectively.  The 
NHLs represent a diverse and heterogeneous group of malignancies.  The 2008 
World Health Organization (WHO) classification of lymphomas includes more than 
60 distinct subtypes of NHL with diffuse large B-cell lymphoma (DLBCL), follicular 
lymphoma (FL) and chronic lymphocytic leukaemia (CLL)/small lymphocytic 
lymphoma (SLL) the most common.  
The aetiology of both HL and NHL is still unclear.  However, current evidence 
suggests that environmental exposures, infectious agents, and both 
immunosuppression and immune activation contribute to the development of these 
diseases.  In addition, as described below, there is compelling evidence for inherited 
susceptibility to HL and NHL.  The search for genetic risk factors has highlighted the 
importance of the human leukocyte antigen (HLA) region (2, 3).  A crucial role for 
HLA in disease pathogenesis is further suggested by observations that HLA class I 
and class II expression is frequently down-regulated in tumour tissue (4, 5).  Taken 
together, the data implicate HLA-mediated interactions in the pathogenesis of both 
HL and NHL.  This review aims to summarise the main findings that have emerged 
from HLA association studies and genome-wide association studies (GWAS) of HL 
and the three most common forms of NHL, namely DLBCL, FL and CLL/SLL. 
Evidence for inherited susceptibility in lymphoma 
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Inherited susceptibility to HL and NHL is supported by several strands of evidence.  
First, the incidence of HL and NHL varies significantly between racial and ethnic 
groups with the Asian population showing one of the lowest incidence rates for both 
diseases (6-8).  Population-based studies in the USA demonstrate that the incidence 
of HL and CLL is consistently low in Asian groups relative to US Whites, suggesting 
some genetic protection against disease, given similar environmental exposures (6, 
8).  Secondly, there is clear evidence of familial aggregation of both HL and NHL.  
Studies of HL indicate a 3-9 fold increased risk of HL in first-degree relatives of index 
cases (9-12).  Furthermore, a study of monozygotic and dizygotic twins 
demonstrated that the co-twin of a monozygotic HL case has a 100-fold increased 
risk of developing the disease (13).  The Swedish Family Cancer database estimated 
the heritability of HL in the white population as 28.4% (14).  Individual case-control 
studies as well as a recent meta-analysis of NHL subtypes also show an increased 
incidence of DLBCL, FL and CLL in patients with a family history of NHL, with CLL 
showing the greatest increase of 8-fold (15-21).  Familial aggregation of CLL cases 
has also been documented in over 100 familial studies (reviewed in 22).  
Collectively, the data support a genetic predisposition to the development of 
lymphoma.  
Human Leukocyte Antigens and Genes 
HLA molecules present pathogen and tumour-derived peptides to T-cells thereby 
initiating the adaptive immune response.  The classical HLA class I molecules, HLA-
A, -B and -C, are heterodimers of a polymorphic α-polypeptide chain and β2-
microglobulin, present endogenous peptides to cytotoxic CD8 positive T-cells 
(CD8+T-cells), and are expressed by almost all somatic cells.  In contrast, the HLA 
class II molecules HLA-DR, -DQ and -DP are heterodimers of α- and β-polypeptide 
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chains, present endocytosed extracellular peptides to helper CD4 positive T-cells 
(CD4+T-cells), and are normally expressed only on antigen presenting cells.      
The highly polymorphic HLA genes are contained within the HLA complex, the 
human equivalent of the major histocompatibility complex, which is located on the 
short arm of chromosome 6 and divided into three regions.  The class I region 
contains genes for the α-chains of HLA-A, B and C and also the three non-classical 
HLAs (HLA-E, -F and –G), which are differentiated by their limited polymorphism and 
restricted tissue expression.  Similarly, the class II region includes genes for HLA-
DR, DQ, and DP as well as HLA-DO and DM, the non-classical class II antigens.  
DQA1 and DQB1 genes encode the α- and β-chains of the HLA-DQ heterodimer 
and, similarly, DPA1 and DPB1 genes encode the respective chains of the DP 
heterodimer.  For DR the situation is more complex as the number of DR genes 
varies between individual MHC regions.  All have a single DRA gene and a DRB1 
gene but some haplotypes have an additional, functional DRB3, DRB4, or DRB5 
gene.  For example, haplotypes containing the DRB1 alleles DRB1*04:01, *07:01 
and *09:01 also have a DRB4 gene.  This results in expression of a second DR 
molecule with α- and β-chains encoded by the DRA and DRB4 genes, respectively 
(23).  Out of a total of 128 class I and 27 class II genes, 42 and 17 encode proteins, 
the majority of which have an established role in immunity.   
The HLA class I and II regions are separated by the class III region.  Although there 
are no HLA genes within this region, it encodes proteins with immune function, such 
as tumour necrosis factor (TNF)-α and -β, heat shock proteins and the complement 
factors C2 and C4.      
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HLA class I and II molecules have similar conformations including a peptide-binding 
groove which contains several pockets.  The pockets accommodate side chains of 
amino acids in the bound peptide and some of these, referred to as anchoring 
pockets, have a critical role in determining peptide-binding specificity (reviewed in 
24).  Polymorphisms in HLA genes lead to amino acid variation within these pockets, 
and this in turn affects peptide binding preferences; however, products of different 
HLA alleles can contain identical anchoring pockets thus enabling grouping of HLA 
alleles into supertypes on the basis of overlapping peptide specificities (25).   
To enable an efficient immune response, HLA molecules must bind a peptide and 
the T-cell repertoire must include clones that recognise the HLA-peptide 
combination.  Absence of either may render an individual susceptible to a given 
disease.  
HLA association studies: caveats and pitfalls 
The analysis of HLA associations with disease is challenging and a number of 
factors need to be taken into consideration.  First, study design and sample size are 
critical but for reasons of practicality are seldom ideal.  In case-control studies, 
spurious results can arise from poor matching between cases and controls, 
diagnostic misclassification and disease heterogeneity, biased case selection, and 
retrospective ascertainment of cases leading to survival bias.  Population 
stratification, resulting from admixture of populations with different ancestry, is a 
particular problem in genetic association studies.  Family-based designs aim to avoid 
the potential confounding effects of population stratification by using parents or 
unaffected siblings as controls for the index case.  However, family-based studies 
are often limited by size.  Small studies frequently report strong associations that 
 7 | P a g e  
 
disappear or become weak when sample size increases.  Sample size is also crucial 
in case-control studies.  To have 80% power to detect a significant association 
(p<0.05) with an allele with a carrier frequency of 0.10 with an odds ratio of 2 
requires >300 cases; following correction for multiple testing of e.g. 50 alleles, this 
number increases to >600.  Thus, most published studies of HLA associations are 
under-powered to detect small effects sizes and associations with rare alleles.  The 
necessary larger-sized studies are usually limited by cost and sample availability.   
Secondly, it is often assumed that the genotyped locus confers 
susceptibility/protection from disease development.  However, the genotyped locus 
may not be causal but rather may be in linkage disequilibrium (LD) with the causal 
variant.  This is a particular challenge in HLA association studies as there is 
extensive LD within the HLA complex and many alleles are inherited in a block.  
Thus, unadjusted analyses frequently show associations with multiple alleles on the 
same haplotype; this is less of problem with DP genes as there is a recombination 
hotspot between DQ and DP.    R2 and D’ values are used to describe the extent of 
LD between two genetic variants.  R2 is a measure of correlation, and high values 
(>0.8) occur when two alleles are present at equal frequency and inherited together; 
an r2 of 1 indicates that only two of the four possible haplotypes are present.  For 
tagging studies, where one marker is used to tag or substitute for another, r2 is the 
important measure; however, in population genetics D’, a measure of recombination 
events between two markers which is not dependent on allele frequency, is generally 
more informative.  A high D’ value indicates that the rarer allele is always inherited 
with the other allele or, in the case of single nucleotide polymorphisms (SNPs), with 
one of the alleles; r-squared is usually lower since most of the time the commoner 
allele is present without the rarer allele.   
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Most HLA association studies describe the frequency of a particular allele (or 
genotype or phenotype) according to case-control status, with unadjusted statistical 
analyses, i.e. not adjusted for the effects of other alleles.  In order to identify potential 
causal alleles, various statistical methods have been used to adjust for effects of LD; 
although generally more informative, this can complicate comparisons between 
studies. 
Thirdly, the methodology used to type HLA alleles has changed dramatically over the 
past 40 years.  Traditionally HLA antigens were defined using serological 
techniques. Whilst serology performed adequately for typing families, it was 
unsatisfactory for typing unrelated donors particularly once the extent of HLA 
polymorphism became known.  The availability of nucleotide sequence data for HLA 
genes allowed the rapid development of PCR-based typing methods.  These can be 
grouped into two categories: (i) those which generate a product containing internal 
polymorphisms, which are then identified using a second technique, e.g. PCR-
sequence specific oligonucleotide probing, PCR-restriction fragment length 
polymorphism; (ii) those in which the polymorphism is identified as part of the PCR 
process, e.g. PCR-sequence specific primer.  These techniques have proven reliable, 
robust and accurate and are currently the most widely used methods.  In recent 
research investigations, HLA alleles have also been imputed from SNPs identified in 
GWAS; as more data are becoming available, this method is becoming increasingly 
reliable.  Ultimately, sequencing is required to unequivocally identify specific alleles.  
Changes in typing methodology coupled with an improved understanding of the HLA 
complex have led to changes in HLA nomenclature, which can complicate 
comparisons across studies.  Serotypes, defined by serological typing, are largely 
separated into class I and II groups and numbered sequentially, e.g. HLA-A1, A2 etc.  
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Broad specificities are sometimes further divided into ‘split specificities’.  With the 
introduction of molecular typing the naming system was altered and allele 
designations now include up to four fields separated by colons.  The first field 
contains an asterisk to denote molecular typing and defines the allele of the gene, 
which often but not always corresponds to the serotype; the second field defines the 
subtype of the allele.  Early HLA association studies generally reported only the first 
field of the descriptor with more recent, higher resolution studies reporting the first 
two fields.  In describing reported HLA associations we have attempted to adhere to 
the nomenclature used in the individual studies.  
Hodgkin lymphoma 
A distinguishing feature of HL, shared by both NLPHL and cHL, is the paucity of 
malignant cells within the tumour mass, which is largely composed of an 
inflammatory infiltrate (26).  Until 2001, HL was classified as a single disease, 
Hodgkin’s disease, with four histological subtypes.  Following the acceptance that 
Hodgkin’s disease is a B-cell derived lymphoma and that lymphocyte predominance 
Hodgkin’s disease has many distinctive features, the disease was renamed HL and 
separated into two main entities, NLPHL and cHL (27).  Based upon the infiltrate 
composition and architecture and the morphology of the Hodgkin and Reed-
Sternberg (HRS) cells, cHL is now further subdivided into four histological subtypes.  
The nodular sclerosis (NSHL) subtype is the most common, accounting for up to 
80% of cases, whilst the mixed cellularity (MCHL) subtype accounts for around 15%.      
In the late 1980s it was recognized that a proportion of cHL cases, in developed 
countries, are associated with the EBV (EBV+cHL) and can be distinguished from 
EBV-negative (EBV-cHL) cases by the presence of the virus within HRS cells (28, 
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29).  EBV association rates differ by cHL subtype, age, gender and geography 
reflecting the complexity of the disease (7, 30, 31).  Many HLA association studies 
were performed before the WHO classification system was introduced and before it 
was appreciated that EBV was aetiologically associated with a subgroup of cases.  
Since most MCHL, but only a minority of NSHL, cases are EBV-positive, MCHL 
histology and EBV-positivity are frequently used as proxies for each other; although 
this can help interpretation, it is important to note that at least half of all EBV+cHL 
cases are of NSHL subtype (our unpublished results).  
Early HLA association studies in Hodgkin lymphoma 
HL was the first disease for which any HLA association was described (32).  Using 
45 sera from multiparous women, Amiel et al (1967) reported an increase in 
frequency of the ‘Payne-Bodmer 4c’ antigen from 23% in healthy controls to 51% in 
HL cases from France.  A similar analysis of Dutch cases failed to confirm these 
results (33).  However, the results were corroborated in 1970 in Australia by Forbes 
et al (1970) who demonstrated an increased frequency of the 4c antigen and further 
showed that this resulted from an increased frequency of W5, one of the two 
specificities recognised by the 4c antibody (34).  Forbes et al (1970) also showed 
that W5 was less common in females with NSHL and more common in females with 
MCHL.  The 4c specificities were subsequently shown to include HLA-B5, B15, B18 
and Bw35 (W5) antigens (35). 
Subsequent investigations using serological typing methods demonstrated an 
increased frequency of HLA-B5, B8, B18 and HLA-A1 subtypes in HL patients (Table 
1) (36-44).  The strongest association was shown for HLA-A1 with a 6-fold increase 
in risk of developing cHL (42).  Despite the well-documented linkage between HLA-
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A1 and B8 antigens, HLA-B8 did not always show a similar increase (39, 43).  
Kissmeyer-Nielson et al (1975) also demonstrated an increased HLA-A1 and A8 
prevalence in MCHL cases compared to NSHL and NLPHL cases (39), suggesting 
subtype-specific HLA associations.  Larger, case-control studies further corroborated 
the association with HLA-A1 and identified a lower prevalence of HLA-A3 and A11 
alleles in HL cases compared to healthy controls, suggesting a potential protective 
effect (Table 1) (35, 36, 45). 
Concurrent family-based studies provided some support for these findings.  Marshall 
et al (1977) investigated seven cases of HL within one family and found no HLA 
haplotype or allele  associated with HL development, although HLA-B8 was detected 
more often in first-degree relatives of cases (46).  Further studies demonstrated an 
increased prevalence of HLA-B18, B35, and B37 in cases within families (47, 48).  
Using a shared versus non-shared HLA approach for sibling pairs, a greater than 
expected HLA identity between siblings with HL was documented (43); however, 
previously reported allele associations were not detected in this study.  Similar 
haplotype concordance was observed between HL-affected siblings in a study of 16 
families where half the families displayed the HLA-A*01-B*08 haplotype (49).   
Investigation of associations with class II alleles lagged behind those of class I 
alleles due to a lack of appropriate reagents.  The earliest observations arose from 
family studies.  In a study of four siblings with HL, HLA typing revealed that all 
carried the HLA-DR5 antigen (HLA-DR*11 and DR*12 gene products) and two were 
also HLA-A1-positive (50).  With no obvious differences in EBV antibody titres, 
chromosomal abnormalities or exposure histories, it was concluded that genetic 
factors were more important than environmental factors in disease pathogenesis. 
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Interestingly, some of the earlier studies performed at a time with much higher 
mortality from HL also observed a survival advantage in association with particular 
HLA class I types (41, 42, 44, 45, 51).  An increased frequency of HLA-A28 and A8 
was observed in HL patients with greater than 15 years and 5 years survival, 
respectively (41, 44, 45).  Although HLA-A1 was associated with increased disease 
risk, it was also associated with improved survival and treatment response (42).  
Patients positive for HLA-Aw19 (HLA-A29, 30, 31, 32, 33 gene products) and B5 
antigens also had a poorer prognosis (51).   
HLA and HL in the era of molecular typing 
Following the introduction of molecular typing methods, attention shifted to HLA 
class II.  Case-control studies demonstrated an increased frequency of HLA-
DPB1*03:01 in white patients, with a relative risk of 1.95 (p < 0.01) in the largest 
study (Table 2) (52-57).  The HLA-DPB1*04:01 allele was significantly reduced risk 
in Asian patients, while there was a non-significant reduction in DPB1*02:01 in white 
patients (52, 53).  Taylor et al (1999) analysed cases by histological subtype and 
gender and demonstrated an increased relative risk for females carrying HLA-
DPB1*03:01 or DPB1*10:01 alleles and a reduced risk for females with NSHL who 
carried DPB1*02:01 or DPB1*11:01 alleles (58).  In one of the first studies to stratify 
cases by EBV status, the HLA-DPB1*03:01 allele was detected more frequently in 
patients with EBV+cHL, but differences by EBV status were not  statistically 
significant (54).   
Familial studies highlighted the importance of the HLA-DRB1*15:01-DQA1*01:02-
DQB1*06:02 haplotype in relation to HL, in particular NSHL, with transmission of the 
haplotype 73% of the time to an affected offspring but only 44% of the time to an 
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unaffected offspring (59).  Analysis of the individual genes in the haplotype revealed 
the DRB1*15:01 and DQB1*06:02 were associated with risk of cHL overall whilst 
DQA1*01:02 was associated only with NSHL.   
A much more detailed, but as yet incomplete, understanding of HLA associations 
with cHL has come from recent HLA typing studies coupled with analysis of 
microsatellites and SNPs in the HLA region.  Typing of tumour EBV status has also 
revealed that associations with EBV+cHL and EBV-cHL are largely distinct.  A 
landmark study by Diepstra et al (2005) analysed microsatellite markers spanning 
the HLA class I, II and III regions in EBV-stratified HL cases and controls.  Two 
consecutive microsatellite markers in HLA class I were associated with EBV+cHL.  
These markers are in LD with HLA-A*01 and HLA-A*02 alleles and subsequent 
studies provided evidence that HLA-A*01:01 is associated with an increased and 
A*02:01 with a decreased risk of EBV+cHL (60, 61).  The effects of these two alleles 
are independent and result in A*01:01 and A*02:01 homozygotes having an almost 
10-fold difference in odds of developing EBV+cHL (62).  The only GWAS to include 
cases typed by EBV status in the discovery analysis (63), identified independent 
associations between two HLA class I SNPs (rs2734986 and rs6904029) and 
EBV+cHL; the effects of these SNPs could be accounted for by the effects of A*01 
and A*02 alleles (63).  Thus, several lines of evidence suggest associations between 
EBV+cHL and these alleles, at least in white populations (Table 1).  In a study of 
Chinese cHL cases, Huang et al (2012) reported that the frequency of A*02:07, an 
allele more common in the Chinese population than in Whites, was increased in 
patients with EBV+cHL but decreased in patients with EBV-cHL relative to controls 
(64). 
 14 | P a g e  
 
Subsequent case-control studies have identified further associations specific to 
EBV+cHL.  In unadjusted analyses, Huang et al (2012) detected a significant 
increase in B37, an allele in LD with A1 (65).  Johnson et al (2015) confirmed an 
association with B*37:01, which was significant after adjusting for the effects of other 
HLA alleles, thus demonstrating that this association is independent of A*01:01 (66).  
In addition, Huang et al (2012) reported an increased disease risk in association with 
the rarer DR10 allele.  Although an increased frequency of DR10 was detected by 
Johnson et al (2015), case-control differences were not significant and a larger 
sample size will be required to validate this association.  In allele selection 
regression modelling, Johnson et al (2015) detected additional associations with 
DRB1*15:01 and DPB1*01:01.  Both alleles were associated with a decreased 
disease risk, suggesting that these alleles could have protective effects; interestingly, 
this association between DRB1*15:01 and EBV+cHL is in the opposite direction from 
that described below for EBV-cHL.     
Analyses of associations with EBV-cHL are more difficult to interpret, largely due to 
issues with LD.  Although only a small number of studies have stratified cases by 
EBV status, EBV-cHL cases constitute the majority of cHL cases in industrialised 
countries, are mainly NSHL, and usually occur in the young adult age group.  
Studies of NSHL and of young adult cHL are therefore likely to reflect associations 
with EBV-cHL (and vice versa).  Taken together, such studies provide compelling 
evidence that DRB1*15:01, DQA1*01:02 and DQB1*06:02, three alleles that are in 
LD, are associated with an increased risk of EBV-cHL (55, 59, 65, 66).  More recent 
studies have shown an association between DRB1*07 and decreased risk of EBV-
cHL (65, 66).  However, as described below, it is not clear whether these alleles are 
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biologically important or whether they are simply tagging another gene(s) or 
regulatory sequence that is critical in disease pathogenesis.  
GWAS have consistently shown that the HLA class II SNP rs6903608, located ~15kb 
centromeric to DRA, is the variant most strongly associated with cHL (Table 3) (63, 
67-70).  The association is specific for EBV-cHL and within this patient subgroup 
there is a significant association with NSHL (63).  Increased disease risk is 
associated with the ‘C’ allele, which is in LD with DRB1*15:01 (r2 = 0.46, D’ = 1), 
DQA1*02:01 and DQB1*06:02 (r2 = 0.37, D’ = 0.91).  In a GWAS of NSHL, Cozen et 
al (2011) identified a 5-variant haplotype, incorporating rs6903608, which was 
superior to rs6903608 alone at predicting disease status (68).  The haplotype 
containing the alleles associated with decreased disease risk, including the T variant 
at rs6903608, was associated with a 60% decreased risk of NSHL; all individuals 
carrying this haplotype were positive for DRB1*07:01.  Although the above results 
suggested that rs6903608, and other class II SNPs, were simply tagging class II 
alleles, this is not borne out by logistic regression modelling.      
Moutsianas et al (2011) imputed classical HLA alleles from SNP data in a study 
which largely included young adult cHL cases.  In unconditional logistic regression 
analysis, DRB1*15:01 and DQB1*06:02 were associated with an increased and 
DRB1*07:01, DQA1*02:01 and DQB1*03:03 with a decreased disease risk, 
consistent with previous studies (71).  Subsequent stepwise logistic regression with 
inclusion of selected SNPs and imputed HLA alleles revealed that most of the class 
II variation could be explained by the SNP rs6903608.  The DPB1 SNP rs2281389 
and DQA1*02:01 allele contributed independent additional signals.  DPB1 alleles 
were not imputed in this study and it was suggested that rs2281389 could be tagging 
the DPB1*03:01 allele, previously associated with increased disease risk.  Since 
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DQA1*02:01 is in almost complete LD with DRB1*07:01 it was not possible to 
reliably determine which allele was contributing the additional signal.  Johnson et al 
(2015) used a Bayesian variable selection method to analyse typed HLA alleles and 
three SNPs, including rs6903608, in a study with stratification of cases by EBV 
status (66).  In the analysis of EBV-cHL without inclusion of the SNPs, DQB1*06:02 
and DRB1*07:01 were associated an increased and decreased disease risk, 
respectively; however, following inclusion of the SNPs in the model, rs6903608 was 
the variant most strongly associated with disease risk.  DQB1*03:01, DRB1*03:01 
and B*15:01 contributed independent smaller effects (66).  Taken together, these 
data suggest that rs6903608 is tagging a gene or regulatory sequence that is 
strongly associated with risk of EBV-cHL.  The most consistent associations with 
DRB1, DQA1 and DQB1 alleles described above are likely to result from LD with this 
variant.     
HLA associations with cHL as a whole largely reflect associations with EBV-stratified 
subgroups (65, 66).  Urayama et al (2012) identified two HLA SNPs that were 
independently associated with ‘total cHL’ with no heterogeneity of effect by EBV 
status – the class I SNP rs2248462 at the MICB gene and the class II SNP 
rs2395185 at HLA-DRA (63).  These SNPs were included in the variable selection 
modelling described by Johnson et al (2015), but neither was selected in the 
resultant models suggesting that their effects are explained by HLA alleles. 
Biological implications of HLA Associations with EBV+cHL 
The biological basis for the relationship between HLA alleles and disease risk is 
unknown.  However, in the case of EBV+cHL, this is premised on the ability of HLA 
class I alleles to present EBV antigens to CD8+T-cells and to induce an effective 
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cytotoxic response.  Interestingly, no EBV-specific T-cell responses restricted by the 
EBV+cHL risk allele HLA-A*01 have been identified to date (72).  This suggests that 
HLA-A*01 is unable to elicit a cytotoxic response to effectively control EBV-infected 
B-cells, or HRS cells, although it can efficiently present peptides from other viruses 
(e.g. CMV and Influenza A (73)).  On the other hand, HLA-A*02:01 alleles effectively 
present a number of EBV-derived peptides (74), suggesting that HLA-A*02-positive 
individuals may control EBV infection more effectively.  
Given the breadth of EBV-specific responses (74), it is surprising that the lack of a 
single allele has such a large effect upon risk of EBV+cHL, perhaps suggesting that 
the critical responses are directed against a small number of antigens, such as the 
EBV latency II antigens expressed by HRS cells.  An alternative hypothesis is that 
HLA-A*01 educes inhibitory effects that influence responses restricted through other 
HLA alleles.  The elevated risk of disease seen in HLA-A*01:01/A*02:01 
heterozygotes compared to HLA-A*02:01 homozygotes (62) provides some support 
for the latter model.   
Similarly, the biological mechanism underlying HLA class II allele associations may 
be due to differing capacities in antigen presentation to CD4+T-cells.  CD4+T-cells 
are primarily known for their helper roles; however, a cytotoxic role and the ability to 
be poly-functional, i.e. simultaneously produce multiple cytokines and effect cytotoxic 
function, have also been demonstrated, particularly in response to viral infection (75-
77).  The specificity, breadth, poly-functional capacity and timing of the CD4+T-cell 
response may all be important for disease development.  Indeed, decreased EBNA-1 
specific CD4+T-cell responses have previously been documented for EBV+cHL 
cases (78).  Variation in HLA alleles might therefore result in modulation of CD8+T-
cell activation and the recruitment and functionality of the CD4+T-cell population.  It 
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is possible that different peptide-HLA combinations modulate the composition of the 
cHL associated infiltrate leading to the observed heterogeneity of cHL, survival of 
HRS cells and prevention of tumour suppression.   
HLA Associations with Non-Hodgkin Lymphoma 
NHL encompasses a heterogeneous group of cancers, 85–90% of which arise from 
B-cells.  It is the sixth most common cancer in the U.S. and the fifth most common in 
the UK.  Together, DLBCL and FL, account for approximately 60% of all NHL cases.  
CLL/SLL is the third most common accounting for around 12% of cases (79).  
Although immune suppression and autoimmune disorders have been identified as 
risk factors for NHL, host characteristics also clearly play a role in this disease and 
its various subtypes (80).     
Similar to cHL, HLA is implicated in NHL susceptibility with early studies showing 
down-regulation of the expression of HLA class II antigens (81).  Several small 
studies have reported links between HLA class II alleles and NHL with conflicting 
results that may be attributable to small sample size, the combined analysis of 
various NHL subtypes, and/or analysis of different ethnic groups (82-84).  In 
contrast, recent analyses of individual subtypes provide more consistent results. 
Diffuse Large B-Cell Lymphoma  
DLBCL itself encompasses a biologically and clinically diverse set of diseases.  
Although the WHO classification system defines more than a dozen subtypes, the 
majority of cases are classified as DLBCL, not otherwise specified (NOS).  Gene 
expression profiling has divided DLBCL-NOS into germinal-centre B-cell like (GCB) 
and activated peripheral B-cell like (ABC) with 15% of cases remaining unclassifiable 
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(85).  These groups have different molecular aberrations and clinical outcomes and 
may have different aetiologies.   
Candidate gene studies and GWAS have identified associations between risk of 
DLBCL and immune-regulatory genes (86).  A large, collaborative study from the 
International Lymphoma Epidemiology Consortium provided evidence that the TNF 
promoter polymorphism (TNF G-308A), which is thought to increase TNF-α 
expression resulting in inflammation, is strongly associated with DLBCL in white 
populations (87).  This SNP is located within the HLA class III region, between the 
class I gene HLA-B and the class II gene HLA-DR.  The common 8.1 ancestral 
haplotype includes the TNF-308A allele (HLA-A1-B8-TNF-308A-DR3-DQ2) 
suggesting that TNF associations may be confounded by linkage with HLA alleles.  
However, Abdou et al (2010) demonstrated that the TNF-A allele was associated 
with increased risk of DLBCL even in the absence of the 8.1 haplotype (88).  Their 
results also suggested that the B*08 allele was independently associated with 
disease risk.  In a recent GWAS meta-analysis, including 3,857 cases and 7,666 
controls of European ancestry, 19 SNPs reached genome-wide significance and 134 
were suggestive of significance (89).  Of these 153 SNPs, 123 mapped to the HLA 
region.  The strongest HLA signal was at rs2523607, located near HLA-B (Table 4).  
Following imputation of classical HLA alleles, only the HLA-B*08 allele and 
rs2523607 variant achieved genome-wide significance (p < 5 x 10-8).  These two 
markers are in LD (r2 = 0.91) and after adjustment for the effect of HLA-B*08, the 
association at rs2523607 was attenuated; consistent with earlier observations, these 
data suggest that HLA-B*08 is the HLA allele most strongly associated with DLBCL.  
Smaller GWAS identified weak associations with the class I SNP rs6457327 and 
class II SNP rs10484561, two SNPs that are strongly associated with FL (see below) 
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(90, 91) and the association at rs10484561 was corroborated in the above GWAS 
meta-analysis (p = 1.5 x 10-4).  Two genotyping  studies of DLBCL patients from 
China and Western Siberia reported evidence of an association at rs2647012, a 
further SNP associated with FL (91-93)  Smaller HLA typing studies have 
documented associations with: DRB1*01 and B*51 (risk) and DRB1*15 and C*03 
(protection) in European populations (94); and B*51, DRB1*09 and DQB1*03 and 
the B*51-DRB1*09-DQB1*03 haplotype (risk) in Korean patients (82).   
Additionally, HLA class I and class II alleles have been associated with clinical 
outcome.  Initial reports suggested that HLA-DR2 (DRB1*15 and *16) negative 
patients had a poorer progression free survival (PFS) and overall survival (OS) (95).  
Later studies demonstrated associations between B*18, B*44, Cw*07 and DRB1*04 
and shorter PFS and OS (94, 96).  HLA-B*18 and B*44 share overlapping peptide 
binding specificity and form part of the B44 supertype.  When all alleles comprising 
this supertype (B*18, B*37, B*40, B*41, B*44, B*45, B*50) were analysed as a 
group, the supertype also showed poorer PFS and OS (94).  
Follicular Lymphoma  
FL is the second most common subtype of NHL, comprising up to 30% of all NHL 
cases worldwide.  Although FL has a relatively long median survival, 8–10 years, 
more than 20% of FLs transform to an aggressive lymphoma with a poor clinical 
outcome.  A defining feature of FL is the presence of the t(14:18) translocation, 
which results in dysregulation of bcl-2 expression.  Akin to cHL and DLBCL, a 
hereditary component is proposed based upon ethnic variation (rarer in Asian 
populations) and an increased risk of FL in first-degree relatives (16, 17).   
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The first GWAS to include samples from FL patients identified an association with 
SNPs within the HLA class I region.  Disease risk was associated with rs6457327 
and neighboring SNPs in a 26 kb block of sequence that overlaps the STG gene 
(C6orf15) and is near psoriasis susceptibility region 1 (PSORS1) (90).  This region is 
close to HLA-C and a later analysis showed that the ‘A’ allele at rs6457327 is 
associated with C*07:01 and B*07:02 (D’ = 0.93 and 1.0, respectively); however, 
there is no evidence that these alleles account for the effect of the SNP.  
Subsequent studies confirmed association with rs6457327 (97, 98); in addition, the 
risk allele ‘A’ and associated genotypes ‘AA’ and ‘AC’ were associated with an 
increased risk of, and, shorter time to, transformation as well as inferior OS (91, 97, 
98).   
In a follow-up GWAS, Conde et al (2010) reported further associations in a region 
including the HLA-DR and HLA-DQ genes (Table 4) (99).  The SNPs with the most 
significant p-values were rs10484561 and rs7755224, two SNPs in complete LD 
telomeric to the HLA-DQB1 gene.  Imputation of surrounding SNPs revealed a 
further four associated SNPs in a 100 kb region of LD including HLA-DQB1 and 
HLA-DQA1, although rs10484561 remained the strongest signal.  One of these four 
SNPs, rs6457614, is a tag SNP for HLA-DQB1*05:01, and follow up analyses 
revealed an association between FL and the extended haplotype DRB1*01:01-
DQA1*01:01-DQB1*05:01 (OR = 2.07).  Subsequent HLA typing studies confirmed 
associations with DQB1*05:01 and DRB1*01:01, as well as an inverse association 
with DQB1*06 (96; 97).  A further GWAS with a larger number of cases in the 
discovery analysis corroborated earlier findings and demonstrated more associations 
(91, 100).  The strongest signal was at rs2647012, and this was independent of the 
association at rs10484561 located 960 base pairs in a centromeric direction.  
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Subsequent fine-mapping, haplotype and coalescence analyses suggested that 
these two SNPs are associated with two distinct haplotypes that have opposite 
effects on risk of FL (91).  HLA typing of class I and II alleles by next generation 
sequencing identified a decreased FL risk in association with DRB1*15 and 
DQB1*06 alleles and showed that carriers of the DRB1*15:01-DQA1*02:01-
DQB1*06:02 haplotype were all positive for the ‘A’ allele at rs2647012 (but not vice 
versa) (101).  This study also extended HLA analyses to DPB1 alleles and identified 
a protective effect of DPB1*03:01.  A GWAS meta-analysis identified a further SNP 
association at rs311722, located downstream of the DPB1 genes, which was 
explained by the DPB1*03:01 association.  The current model of FL therefore 
suggests that the class I SNP rs6457327, the haplotypes HLA-DRB1*01:01-
DQA1*01:01-DQB1*05:01 and DRB1*15:01-DQA1*02:01-DQB1*06:02, and 
DPB1*03:01 are all independently associated with risk of FL.   
To determine whether specific coding variants within HLA genes contribute to the 
above associations identified by GWAS and HLA allele typing, Foo et al (2013) 
imputed SNPs, classical HLA alleles and coding variants across the HLA region 
(102).  They identified a hexa-allelic amino acid polymorphism at position 13 of the 
HLA-DR beta chain that showed a stronger association with FL than any other 
variant or SNP that was tested.  From a possible six amino acids, two were classified 
as high risk (Tyr and Phe), two as low risk (Ser and Arg), and two as moderate risk 
(His and Gly).  There was a 4.2-fold difference in risk between subjects carrying two 
alleles encoding high-risk amino acids and those carrying two alleles encoding low-
risk amino acids.  Further analysis revealed that the risk allele ‘C’ from rs10484561 
tags haplotypes carrying the allele encoding the high risk Phe, whilst the protective 
allele ‘T’ from rs2647012 tags haplotypes carrying the allele encoding the low risk 
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Ser  residue.  The data suggest that the DRB1 polymorphism at position 13 is the 
primary driver of the above DR and DQ associations, thus advocating a HLA-DR 
antigen-driven mechanism in the pathogenesis of FL. 
HLA alleles have also been investigated in relation to outcome.  HLA-A*01 and the 
ancestral 8.1 haplotype (A*01-B*08-DR*03) have been associated with poorer OS 
and HLA-Bw4 and DRB1*13 with improved OS (96).   
Chronic Lymphocytic Leukaemia /Small Lymphocytic Lymphoma  
CLL is an indolent malignancy resulting from the accumulation of slowly proliferating 
CD5-positive neoplastic B-cells, which accounts for about a quarter of all leukaemias 
in Western countries.  Small lymphocytic lymphoma has the same 
immunophenotype and is essentially the same disease but the malignant cells are in 
the lymph nodes and spleen rather than the blood.  Around half of all CLLs have 
evidence of somatic hypermutation in their immunoglobulin heavy chain variable 
region genes (IGHVs), and IGHV mutation status is used to divide CLLs into two 
subgroups.  Cases with mutated IGHV have a much better clinical outcome.   
Early case-control and family-based HLA typing studies did not identify consistent 
associations with HLA alleles, most probably because of small case numbers.  
However, later studies provide support for some of the earlier findings, and the work 
of Dorak et al (1996) focused attention on DRB4 and associated haplotypes (103).  
Machulla et al (2001) compared the frequency of HLA class I and II alleles in 101 
cases and 157 controls using molecular and serological typing methods (104).  PCR-
based typing revealed a striking increase in DRB4*01:03 alleles among cases (RR = 
2.74, p = 0.0025); higher frequencies of DRB1*04:01, DQB1*03:02 and DPB1*03:01 
and a lower frequency of DQB1*02:02 alleles were also detected.  None of these 
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differences remained significant after correction for multiple testing.  The haplotype 
DRB1*04:01-DRB4*01:03 was also increased and CLL-specific LD was observed 
between these alleles.  The association with DQB1*03:02 was thought to result from 
LD with DRB1*04:01-DRB4*01:03 on the ancestral haplotype HLA-Cw3-B62-DR4-
DQ8, which is frequent in white populations.  There was no evidence of LD between 
DPB1*03:01 and the other risk alleles.  
In by far the largest study to date, Gragert et al (2014) compared HLA genotypes 
from 3491 US white, 397 African-American and 90 Hispanic CLL patients with 
50,000 controls from each of these populations (105).  Cases were ascertained 
through the National Bone Marrow Program and this is likely to have resulted in a 
bias towards patients with more severe disease and younger age.  A large number of 
allele and haplotype associations were identified, some of which had been previously 
reported.  In Whites, 12 alleles were decreased and 16 increased in frequency with 
DQB1*05:04 (OR = 5.62) and DRB1*04:03 (OR = 0.67) having the highest and 
lowest ORs, respectively; despite the size of the study, effect sizes of many of the 
associations were modest with upper or lower bounds of the 95% confidence 
intervals close to one.  The DRB4*01:01 allele and haplotype DRB4*01:01-
DRB1*07:01-DQB1*03:03 were strongly associated with increased disease risk in all 
study populations, i.e. Whites, African Americans and Hispanics.  Both DRB4*01:01 
and this extended haplotype are much rarer in African Americans than whites (allele 
frequency 18.2% versus 29.7%, haplotype frequency 0.3% versus 3.4%), and it is 
therefore possible that this contributes to the lower incidence of CLL in African 
Americans.  C*04:01, an allele found at relatively high frequency in African 
Americans, was associated with decreased disease risk but only in the African 
American population.  Associations were confirmed with A*02:01 (OR = 1.2), which 
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had been identified following imputation of HLA alleles in a GWAS (106), and with 
the haplotype A*02:01-B*15:01-DRB1*04:01 (OR = 1.41).  A further haplotype 
association with A*01:01-C*07:01-B*08:01-DRB1*03:01-DQB1*02:01 was also 
confirmed at higher resolution (OR = 0.83).  In addition, homozygosity at all three 
class I alleles was shown to significantly increase risk of CLL (105).  DPB1 
associations were not investigated.   
GWAS have identified few associations between HLA SNPs and CLL.  Di Bernardo 
et al (2013) reported an association with the HLA class I SNP rs6904029, which is 
also associated with EBV+cHL, and this led to the identification of the association 
with A*02:01 described above (Table 4) (106).  Following analysis of familial CLL 
cases included in a larger GWAS, Slager et al (2011) identified association with five 
SNPs in a region of HLA class II that includes the DQA1 and DRB5 genes (Figure 1).  
Following conditional analyses of the five SNPs, only rs674313 retained significance 
thus suggesting that these SNPs are tagging the same locus (107).  Imputation of 
HLA alleles in this region was not performed.  In contrast to the findings for cHL and 
FL described above, the strongest signals in GWAS were from non-HLA SNPs.  At 
least 30 common risk variants have been identified thus far, with several in proximity 
to genes involved in apoptosis or telomere function (108, 109).  These data are 
consistent with the idea that co-inheritance of multiple low risk variants is likely to 
explain the heritability in CLL/SLL. 
Summary and Conclusions  
Recent GWAS and HLA typing studies provide consistent and reliable evidence 
linking specific HLA polymorphisms with subtypes of human lymphoma.  Clustering 
of SNPs associated with cHL, FL and CLL within the HLA class II region is perhaps 
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one of the most striking observations to emerge from these studies.  However, 
associations within this region, which encompasses the HLA-DRA, DRB1 and DQB1 
genes, are distinct for each of the three diseases (Figure 1).  Stratification of cHL 
cases by EBV status further demonstrates that the association with the DRA SNP 
rs6903608 is particular to EBV-cHL.  In contrast, EBV+cHL is strongly associated 
with the class I allele HLA-A1*01, an allele first linked to HL over forty years ago.  
Several alleles are associated with multiple lymphoma subtypes.  Associations with 
DPB1*03:01 and DRB1*15:01 are described for FL and cHL; however, associations 
with FL are in the opposite direction from those reported for total cHL and EBV-cHL 
although the DRB1*15:01 association is in the same direction to that recently 
reported for EBV+cHL.  Likewise, the HLA-A*02:01 allele is associated with 
increased risk of CLL but reduced risk of cHL.  In contrast, the class II SNPs 
rs10484561 and rs2647012 are associated with increased risk of both FL and 
DLBCL, albeit with less significance for DLBCL, possibly implying that the DLBCL 
association is confined to a subset of DLBCLs with features more closely related to 
FL.  Although the evidence for specific HLA associations with lymphoma subtypes is 
compelling, understanding the biology underlying these complex associations awaits 
further study.   
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Figure Legends 
Figure 1.  Location of lymphoma-associated SNPs on chromosome 6 
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Schematic of chromosome 6 showing relative positions of SNPs associated with risk of 
classical Hodgkin lymphoma (cHL, blue), diffuse large B cell lymphoma (DLBCL, grey), 
follicular lymphoma (FL, red) and chronic lymphocytic leukaemia (CLL, purple).  SNPs 
associated with more than one disease are highlighted in green (FL and DLBCL) and brown 
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HL subgroup association HLA Allele 
Direction of 
risk 
















HL (<1 year post diagnosis) A*03 Decreased 
HL (<1 year post diagnosis) A*11 Decreased 
HL (>5 years post diagnosis) B*08 Increased 























Serological HL (MCHL, males >30 years) 
A*01 Increased 
B*08 Increased 






HL (>40 years) B*08 Increased 
HL (<40 years) B*12 Increased 
Hansen et al (1977) United States Case- 137 cases Serological HL A*01 Increased 
control 855 controls A*33 Decreased 





Serological HL B*18 Increased 





10 long term 
survivors 
30 new cases 
1263 controls 
Serological 
HL (long term survivors) A*28 Increased 
HL, NSHL B*18 Increased 
Greene et al (1979) United States 
Family-
based 
411 unrelated cases 
629 controls 





Osoba et al (1980) Canada Case series 79 cases Serological 






Conte et al (1983) Italy 
Family-
based 
4 cases  
15 relatives 
Serological NSHL B*18 Increased 





Serological HL A*01 Increased 






























cHL B*05 Increased 
Huang et al (2012) China 
Case-
control 
161 cases Molecular EBV+cHL A*02:07 Increased 
119 controls  EBV-cHL A*02:07 Decreased  











EBV-cHL B*15 Increased 
HLA class I associations by study for HL or HL subgroup. HL, Hodgkin lymphoma; cHL, classical Hodgkin lymphoma; EBV, Epstein-Barr virus; NSHL, nodular 
sclerosis Hodgkin lymphoma; MCHL, mixed cellularity Hodgkin lymphoma; LDHL, lymphocyte depleted Hodgkin lymphoma 
Results highlighted in bold are significant, p<0.05 
Ϯ includes subjects from Falk et al (1971) and Falk et al (1974)  




Table 2.  HLA class II associations with HL 
Study 
Ethnicity or 








association HLA Allele Direction of risk 





























Asian DPB1*04:01 Decreased 







Asian DPB1*04:01 Decreased 






















Molecular HL DPB1*03:01 Increased 


















Molecular EBV+cHL DPB1*03:01 Increased 











NSHL DQA1*01:02 Increased 









EBV+cHL DR10 Increased‡ 














HLA class II associations by study for HL or HL subtype. HL, Hodgkin lymphoma; cHL, classical Hodgkin lymphoma; EBV, Epstein-Barr virus; NSHL, nodular 
sclerosis Hodgkin lymphoma  
Results highlighted in bold are significant, p<0.05, ‡ p<0.001 
Ϯ includes subjects from Tonks et al (1992) 
~ includes subjects from Taylor et al (1996) 
*adjusted for effects of other HLA alleles and selected SNPs 
  












cHL, classical Hodgkin lymphoma;  EBV, Epstein-Barr virus;  NSHL, nodular sclerosis Hodgkin lymphoma 
Ϯ replication group includes a subset of subjects from Urayama et al (2012)  
§ includes the subjects from Enciso-Mora et al (2011) 
*significant in independent replication 
# significant in technical replication 
α significant association with EBV-cHL in replication set 
Variants rs9268542 and rs9268528 are in LD (r2 = 1), and there is some degree of LD between these variants and rs2395185 (r2 = 0.38).  SNPs identified by 




















cHL rs6903608*α C 1.81 8.12 x10-23 HLA-DRA 







NSHL rs2858870* G 0.4 1.69 x10-8 HLA-DRA 
NSHL rs6903608* C 1.6 3.52 x10-10 HLA-DRA 
NSHL rs9268542 G 1.6 5.35 x10-10 HLA-DRA 
NSHL rs9268528 G 1.6 1.19 x10-9 HLA-DRA 
NSHL rs204999 G 0.5 1.44 x10-9 PRRT1 





cHL rs2248462*# A 0.61 1.3 x10-13 MICB 
cHL rs2395185*# T 0.56 8.3 x10-23 HLA-DRA 
EBV+cHL rs2734986# C 2.45 1.2 x10-15 HLA-A 
EBV+cHL rs6904029# A 0.46 5.5 x10-10 HcG9/HLA-A 
EBV-cHL rs6903608# C 1.71 3.2 x10-27 HLA-DRA 






cHL rs6903608 C 1.62 5.36 x10-27 HLA-DRA 
cHL rs2395185 T 0.66 4.44 x10-16 HLA-DRA 













p-value Candidate Gene/Haplotype 
DLBCL 







rs6457327 A 0.79 2.7 x 10-2 C6orf15 (STG)/ PSORS1 
Smedby et al (2011) Denmark 
379 cases 
791 controls 
rs10484561 C 1.36 1 x 10-7 HLA-DQB1 
Cerhan et al (2014) European 
2661 cases 
6221 controls 
rs2523607 A 1.45 7.1 x 10-10 HLA-B*08:01 
FL 







rs6457327 A 0.55 1.1 x 10-5 C6orf15 (STG)/ PSORS1 






rs10484561 G 1.81 5.88 x 10-5 
HLA-DQB1  
rs7755224 G 1.8 2.6 x 10-5 
rs6457614 G 1.75 7.06 x 10-5 HLA-DQB1*05:01 
rs4947332 T - - HLA-DRB1*01:01 
rs1794265 T - - HLA-DQA1*01:01 








rs2647012 T 0.6 1 x 10-7 
DRB1*15:01-DQA1*01:02-
DQB1*06:02 






rs3117222 A 0.66 1.45 x 10-7 HLA-DPB1*03:01 





rs615672 C 1.95 6.42 x 10-5 
HLA-DRB5 
rs674313 T 2.4 1.12 x 10-6 
SNP associations arranged by lymphoma type.  DLBCL, diffuse large B-cell lymphoma;  FL, follicular lymphoma;  CLL, chronic lymphocytic leukaemia. 
*meta-analysis includes Conde et al (2010) and Smedby et al (2011) 
 
 
rs502771 C 1.93 1.07 x 10-4 
rs9272219 T 2.32 1.65 x 10-6 
HLA-DQA1 
rs9272535 A 2.33 1.33 x 10-6 






rs6904029 A 1.32 1.38 x10-4 HcG9/HLA-A 

































Figure 1. Position of lymphoma-associated SNPs on chromosome 6 
HLA-DRB1 
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